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aC ardiovascular disease (CVD) is a significanthealth problem in India with an estimated3.7 million (29%) deaths and 32 million
11%) disability-adjusted life-years attributed to the
isease each year (1,2). The CVD burden is expected
o increase further with effective control of communi-
able diseases, decreasing childhood mortality, aging
f the population, and changing lifestyles (1). Those
ith CVD in India tend to be younger, with 52% of
ardiovascular deaths occurring before the age of 70
ears compared with just 23% in more developed
ountries (3). This has major socioeconomic conse-
uences (4), and the development and implementa-
ion of effective, low-cost, preventive strategies are
ublic health priorities.
Approximately 70% of the Indian population (700
illion) reside in villages and have limited access to
ealth care (5). The management of chronic diseases
resents a particular challenge in this setting because
f the paucity of healthcare facilities, a lack of pro-
ider training, and the limited capacity of the popula-
ion to pay for care (4). There is, however, an abun-
ance of research indicating the potential for clinical
nd public health interventions to control the risks of shronic conditions if effective, affordable, and sustain-
ble mechanisms for delivery can be identified (6,7).
or example, the use of blood pressure–lowering,
ipid-lowering, and antiplatelet therapy in high-risk
ndividuals is of well-established benefit and likely
o provide significant risk reductions in rural India
f the practicalities of treatment can be resolved (8).
ikewise, the role of behavioral factors in causing
VD and the potential for changes in smoking,
iet, and physical activity to reduce risks are clearly
pparent (9).
What is missing is evidence of how to deliver inter-
entions for chronic disease control (10–12). In set-
ings such as rural India, the focus has been on mater-
al and child health programs delivered through
rimary care centers staffed by nonphysician health
orkers (NPHWs). Expanding the capacity of this
nfrastructure to address the burgeoning chronic dis-
ase problem has been identified as 1 approach worth
xploring (13). The intervention used in this study
ncorporated a population-wide approach provided
hrough community-based health promotion and an
bsolute risk–based strategy for delivery by clinical
ervices. The design of the intervention has been sig-
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tion recommendations for a CVD risk management pack-
age for low- and middle-income countries (14).
Accordingly, the goal of this study was to develop, imple-
ment, and evaluate 2 CVD prevention strategies that could
potentially be delivered by NPHWs: 1 based on a clinical
approach and 1 based on health promotion. Further de-
tails about the rationale and design of the study were
previously published (15).
Methods
The Rural Andhra Pradesh Cardiovascular Prevention
Study (RAPCAPS) was a cluster-randomized trial con-
ducted in the Indian state of Andhra Pradesh between 2006
and 2008 (15). The study was coordinated by the George
Institute for Global Health in Sydney, Australia, in collabo-
ration with the Byrraju Foundation of Hyderabad, India,
and the Centre for Chronic Disease Control in New Delhi,
India. The project was reviewed and approved by the ethics
committees of the University of Sydney, Sydney, Australia,
and the CARE Foundation, Hyderabad, India. No formal
ethics review processes exist in the villages, but the study
was explained and discussed with the Panchayat (commit-
tee of village elders) in each village to obtain their consent
to participate. The study collaborators met with the village
elders at the beginning of the study and explained the ratio-
nale of study to them. Informed consent was obtained from
all individuals involved in outcome surveys before the com-
mencement of the evaluation.
The study was conducted in 44 villages in the East and
West Godavari districts of Andhra Pradesh. Villages were
eligible if the Panchayat agreed to participate there was a
village health center, there was a list of residents, and the
village was broadly representative of the villages in the re-
gion. Population registers in 90 of the villages in this area
had been regularly updated by the Byrraju Foundation.
The average population size of participating villages was
3,938 (range, 1,216 to 8,626), and an estimated 46% were
age 30 years or older.
Randomization. The randomization process was done
centrally by epidemiologists based at the George Institute
for Global Health in Sydney. The randomization unit was
a cluster (the village). Villages were stratified according to
geographic region (East or West Godavari), population size
(large, 4,500 to 8,000; medium, 2,500 to 4,500; small,
1,000 to 2,500), and distance from the nearest large town(20 km, 20 km). For each of the 22 pairs, 1 village was
randomly allocated to the intervention group and the other
to the control group. This was done first to the clinical in-
tervention group versus the control group, and the process
was repeated for allocation to the health promotion inter-
vention group versus control group (Fig. 1).
Intervention and control. There were 2 CVD preven-
tion strategies tested, 1 based on a clinical approach and 1
based on health promotion, and both were designed specifi-
cally for the resource level and circumstances of the area.
The interventions were, by their nature, delivered in an
unblinded manner.
Clinical intervention and control. The primary objec-
tive of the clinical intervention was to increase the identifi-
cation of people at high risk of cardiovascular events (indi-
viduals with a history of heart attack, stroke, or angina)
who would be eligible for proven preventive drug therapies.
To achieve this, we developed a simple hard copy algorithm
designed for use as an opportunistic screening tool by the
primary healthcare providers (mostly NPHWs with only
limited physician involvement). Practitioners were trained
to screen all adults, presenting for any reasons, by asking 3
simple questions about the occurrence of previous CVD. In
the case of a positive response, the management algorithm
that directed key treatment decisions was applied and a
completed hard copy was stored in the village health center.
After the initial assessment by a NPHW, a second review
by a physician was sought with the physician recording his
or her decisions alongside those of the NPHW. Two days
of training on the algorithm was provided at baseline to
physician and NPHW alike, with half-day refresher train-
ing every 6 months. Occasional additional remedial train-
ing was given if there were uncertainties regarding perfor-
mance. In the villages assigned to the control group, the
primary care providers continued their usual practices.
Health promotion intervention and control. The pri-
mary objective of the health promotion intervention was to
increase the knowledge of the adult population with regard
to 6 key health behaviors related to CVD. To achieve this
goal, we developed a program of activities that could be
implemented in the village. The campaign included post-
ers, street theater, rallies, and community presentations
designed to convey messages about stopping tobacco use,
heart-healthy eating, and physical activity. A different com-
ponent of the intervention was implemented each month.
p
f
Num
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additional health promotion campaign planned.
Outcomes. The primary outcomes were different for
the clinical intervention and the health promotion inter-
vention, reflecting the different principal targets of each
component, both in terms of the outcome used and the
group in which it was evaluated. The population survey
methods used to collect the data for these outcome as-
sessments were, however, basically the same for both
interventions and were done in exactly the same way in
every village, regardless of its assignment to intervention
or control between 12 and 24 months after
randomization.
The primary outcome for the clinical intervention group
was the proportion of high-risk individuals in the village
who were identified. This was estimated through the con-
duct of a door-to-door survey that sought to visit every
household in all 44 participating villages. An interviewer
inquired about the presence in the household of anyone age
30 years or older with a history of heart attack, stroke, or
angina (a high-risk individual). If a high-risk individual was
identified, consent was sought; a questionnaire was com-
leted; blood pressure, weight, height, and waist circum-
Figure 1 Study Flow Chart Showing Dual Randomization anderence were recorded; and a nonfasting glucose andurine dipstick was used to obtain blood, protein, and
glucose samples. In addition, a fasting venous blood
sample for assay of venous glucose, cholesterol, and cre-
atinine was obtained from a subsample of high-risk indi-
viduals. The primary outcome was estimated for each
village by dividing the number of high-risk patients who
responded “yes” to the question “have you been assessed
for your risk of heart disease/stroke/angina by a health-
care provider in the past 12 months?” by the total num-
ber of high-risk individuals identified in the village. The
other data collected were used for the evaluation of the
secondary outcomes.
In addition, for each high-risk individual identified in
an intervention village, the hard copy of the algorithm on
which the healthcare workers recorded their management
recommendations with regard to drug and nondrug inter-
ventions was collected from the relevant health center.
The primary outcome for the health promotion inter-
vention group was the mean number of correct answers
given to 6 questions about behavioral determinants of
CVD. This was estimated by administering the same ques-
tionnaire and physical examination as described previously
to an age- and sex-stratified sample of as many as 100
bers Evaluated for the Respective Outcomesadults age 30 years or older in each village. Individuals were
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ing 1 individual from a pre-specified age and sex stratum.
No fasting venous blood samples were collected from this
general population sample, except when the individual was
also a part of the high-risk group. The primary outcome
was calculated for each village by dividing the number of
correct responses to the questions by the total number of
questions asked. The other data collected were used for the
evaluation of the secondary outcomes.
The secondary outcomes were 1) use of appropriate
drug treatments, 2) receipt of advice about nondrug pre-
ventive strategies, 3) adopting of nondrug preventive strate-
gies, and 4) physical and laboratory measurements (includ-
ing blood pressure, body mass index, waist circumference,
and random capillary blood glucose for all and fasting ve-
nous blood glucose, total cholesterol, blood creatinine for a
subsample of high-risk individuals). In addition the pri-
mary outcomes for each intervention were also evaluated
for the alternate intervention.
Statistical power. The underlying assumptions were that
there would be 1,500 adults age 30 years or older in each
illage and that 5% of them would meet the definition of
high-risk (10) (75 people on average in each village, 3,300
in the 44 villages). For the evaluation of this outcome,
there was projected to be 80% power (2-sided alpha 
0.05) to detect a difference of 10% in the proportion of
high-risk individuals identified between randomized
groups. This estimate assumed that only one half of the
high-risk adults in each village would actually participate in
the survey and that one fourth would be identified in the
control villages (increasing to 35% in the intervention
group villages). Our sample size calculation also assumed an
intracluster correlation coefficient of 0.05. A similar calcu-
lation was done for the effect of the health promotion cam-
paign with the design having similar power to detect a 10%
difference in knowledge levels between randomized groups.
Analysis. The primary analyses of the clinical intervention
were done at the cluster level with the effect on the propor-
tion of high-risk individuals determined from a weighted t
test in a regression model. The primary computation was of
the marginal effects with secondary analyses incorporating
both interventions as factors as well as an interaction term.
These secondary analyses did not produce different find-
ings. The weights used were the total number of high-risk
individuals in each village. Subsidiary analyses using indi-
vidual patient data, with a variable indicating whether apatient has been identified as high risk, were performed
using generalized estimating equations with exchangeable
correlation structures. The same approach was used to in-
clude the primary and secondary factors.
A strategy similar to that used for evaluating the algo-
rithm effects was used to assess the effects of the health pro-
motion intervention on knowledge levels. Primary testing
was done using a weighted linear regression. For this
knowledge outcome that was measured in a population
sample, the weighting was by the inverse of the sampling
probability. Once again, the primary analysis was the mar-
ginal analysis and the inclusion of the second factor and the
interaction term did not alter the findings.
The same methods were used for the analyses of the
effects on the secondary outcomes. All analyses were con-
ducted on an intention-to-treat basis. A p value 0.05 was
deemed unlikely to have arisen by chance alone, although
interpretation of the findings was made in light of the large
number of comparisons made. All tests were 2 sided, and
analyses were conducted using STATA (StataCorp, College
Station, Texas) and SAS version 9.2 (SAS Institute, Cary,
North Carolina).
Results
Outcome assessment surveys were conducted a mean of 18
months after introduction of the interventions. A total of
1,137 high-risk individuals were identified and surveyed,
and 1,135 (average of 26 per village; range, 5 to 61 per
village) who had complete data on the primary outcome for
the clinical intervention were included in these analyses
(Table 1). The survey of the general population collected
data on the primary knowledge outcome for the health
promotion intervention from 3,712 individuals age 30
years or older (Table 1). The general population survey
achieved a response rate of 84%, with 4,400 invited to at-
tend and an average of 84 individuals were included from
each village (range, 73 to 94). Response rates did not differ
between intervention and control villages. Among the high-
risk individuals, 37% (419) reported myocardial infarction,
49% (557) stroke, and 18% (205) angina, with documents
supporting the diagnosis cited by the survey staff for 53%
of myocardial infarctions, 26% of strokes, and 61% of the
cases of angina.
Effects of the clinical algorithm among high-risk
patients. In the villages where the primary healthcare
workers were trained to opportunistically screen with the
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that they were screened for CVD was 12% higher (inter-
vention villages, 63.4 % vs. control villages, 51.4%; p 
0.026) (Table 2). Sensitivity analyses performed that in-
cluded a factor for the health promotion intervention (p 
0.026) and used the approach based on the generalized
estimating equation (p  0.011) did not change the con-
clusion. An intracluster correlation coefficient of 0.093 was
observed for this endpoint. There were no detectable effects
of the clinical algorithm on any of the secondary outcomes
evaluated (all p values 0.33) (Table 2).
There were 1,054 copies of written algorithms com-
pleted by NPHWs in the intervention villages. For 490
(46%) of these, we had records of a subsequent assess-
ment by a physician visiting the primary healthcare cen-
ter. In 15 cases (3%), the physician reclassified the indi-
vidual as low risk, and in a small number of cases, the
physician recommended that one or the other treatment
be withheld for particular individuals. The greatest dis-
crepancy was for beta-blockers in which the NPHWs
recommended therapy for 97.9% and the physicians for
92.3%. Overall, the recommendations for drug therapy
made by the NPHWs guided by the algorithm were ex-
actly the same as those made by the physicians in 88.5%
(185 of 209) of cases of suspected stroke and 87.2%
(253 of 290) of cases of suspected heart attack or angina
Demographic Characteristics of Individuals Included in OutcomeTable 1 Demographic Characteristics of Individuals Included
Algorithm
(n  82,646)
High-risk individuals
No. sampled 592
Mean age, yrs 61.1
Female, % 54.1
Literate (able to read and write), % 45.1
No formal schooling, % 35.0
University graduate or higher education, % 2.9
Median monthly household income, rupees 1,500
Population sample 30 yrs
No. sampled 1,839
Mean age, yrs 50.5
Female, % 46.8
Literate (read and write), % 43.3
No formal schooling, % 39.6
University graduate or higher education, % 2.2
Median monthly household income, rupees 1,500(Table 3). iEffects of health promotion among adults age 30 years
or older. There was no detectable effect of the health pro-
motion intervention on the primary outcome of knowledge
about 6 lifestyle factors affecting CVD risk (p  0.15)
Table 4). Individuals in the villages who received a health
romotion intervention were significantly more likely to
void consumption of oily foods (p  0.01), but aside from
his one statistically significant finding, there were no other
etectable differences between the groups randomized to
ealth promotion or control. The intracluster correlation
oefficient for this analysis was 0.074.
iscussion
his trial provides clear evidence that NPHWs can be
rained to reliably identify individuals at high cardiovascu-
ar risk with a simple algorithm and shows that they can use
he tool to identify the correct preventive therapy in the
ajority of cases. The absence of effects of the algorithm
n secondary outcomes, such as the number of drugs pre-
cribed or physiologic parameters such as blood pressure
nd lipid level, is not surprising. NPHWs in India are not
uthorized to prescribe treatment and had no authority to
o so in this trial. To obtain treatment, patients in this trial
equired a second consultation and a prescription from a
hysician. Many individuals would have been unable to
ccess a physician, and even among those who could, there
yses by Randomized Grouputcome Analyses by Randomized Group
o Algorithm
n  90,640)
Health Promotion
(n  83,155)
No Health Promotion
(n  90,131)
543 594 541
61.8 61.3 61.6
62.3 56.3 59.8
45.5 44.4 46.2
37.0 34.2 37.9
2.8 2.7 3.0
1,500 1,500 1,500
1,873 1,868 1,844
50.7 50.4 50.8
47.1 47.3 46.6
40.3 41.8 43.4
42.5 42.2 40.0
1.7 1.7 2.2
1,500 1,500 1,500Analin O
N
(s a high likelihood that therapy would not be used long
nding o
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cian care would have been prohibitive.
NPHWs are the backbone of primary healthcare in In-
dia, and consultations with NPHWs typically cost a frac-
tion of the price of consultations with physicians (16,17).
However, most NPHWs are trained only in maternal and
child health and the delivery of care for communicable dis-
eases. There is good evidence that NPHWs in India have
made significant improvements in maternal and child
health by providing basic services to many at an affordable
price (18,19). Our study suggests that a policy that added
to the skills of NPHWs in the diagnosis and treatment of
CVD might also deliver significant benefits for noncom-
municable diseases, which are now the leading causes of
death in most parts of the country.
The potential for NPHW-led services in India might be
further enhanced by ongoing developments in the country’s
Effects of the Clinical Algorithm Compared With Control on PrimAmong Hig -Risk IndividualsTable 2 Effects of the Clinical Algorithm Compared With ConAmong High-Risk Individuals
(
Primary outcome
Proportion of high-risk individuals identified, %
Secondary outcomes
Mean no. of correct answers to 6 knowledge questions
Mean no. of 6 lifestyle practices received advice about
Mean no. of days eat fruit
Mean no. of days eat green leafy vegetables
Mean no. of days eat oily food
Mean no. of days eat salty food
Mean no. of days do light physical activity
Mean no. of days do medium/heavy physical activity
Mean no. of recommended drugs used
Proportion taking 2 recommended drugs, %*
Proportion not currently using tobacco, %
Proportion with BP measured in past 24 months, %
Proportion with cholesterol measured in past 24 months, %
Proportion with blood or urine glucose assay in past 24 months, %
Mean body mass index, kg/m2
Mean waist circumference, cm
Mean systolic BP, mm Hg
Mean diastolic BP, mm Hg
Mean total cholesterol, mmol/l
Mean creatinine, mmol/l
Mean blood glucose, mmol/l
Values are weighted mean values for high-risk individuals (or proportions of high-risk individua
group. *Aspirin, beta-blocker, diuretic, angiotensin-converting enzyme inhibitor, or statin depe
BP  blood pressure.generic drug industry. Recent advances in the developmentof fixed-dose combination vascular “polypills” driven by
Indian pharmaceutical companies have great potential to
make vascular prevention even more achievable (20–22). A
single once-daily treatment would be a much more straight-
forward plan than current multipill therapies and poten-
tially could be prescribed to high-risk patients by trained
NPHWs (23). Furthermore, if the polypill is sold at low
cost, drug costs for vascular prevention would be manage-
able for much larger numbers of patients.
Although NPHWs were able to provide correct diagno-
sis and treatment to most high-risk individuals, there is
little doubt that they would make more diagnostic and
management errors than trained physicians. Fortunately,
the adverse impact of such errors is likely to be minimal.
Patients who are misclassified as low risk will miss out on
potentially lifesaving treatment, but in a situation in which
most patients are currently untreated, this would seem ac-
nd Secondary Outcomeson Primary and Se ndary Outcomes
hm
92)
Control
(n  543)
Mean Difference
(SE) p Value
51.4 12.0 (5.20) 0.03
5.7 0.01 (0.12) 0.96
5.6 0.03 (0.14) 0.82
2.1 0.13 (0.14) 0.38
1.9 0.07 (0.09) 0.44
9 0.67 0.03 (0.07) 0.72
1.0 0.01 (0.11) 0.96
5.8 0.10 (0.19) 0.61
2.9 0.00 (0.25) 0.99
2 0.60 0.02 (0.07) 0.73
16.4 0.84 (2.52) 0.74
80.1 1.14 (3.10) 0.71
93.6 0.87 (1.97) 0.66
35.2 3.34 (3.99) 0.41
76.6 0.75 (3.36) 0.82
24.0 0.26 (0.27) 0.34
88.7 0.12 (0.76) 0.88
146.0 0.36 (1.81) 0.85
82.0 0.62 (0.93) 0.51
3 4.37 0.04 (0.11) 0.72
0 0.10 0.00 (0.01 0.75
6 6.02 0.04 (0.29) 0.90
the mean differences presented as levels in the intervention group minus levels in the control
n disease state.ary atrol
Algorit
n  5
63.3
5.7
5.6
2.0
2.0
0.6
1.0
5.9
2.9
0.6
17.2
82.1
94.4
38.5
77.4
24.2
88.6
146.0
82.0
4.3
0.1
6.0
ls) withceptable. More importantly, low-risk patients assigned in-
Analyses b sequent
*Overall ag de.
group. *As
BP  blo
1194 Joshi et al. JACC Vol. 59, No. 13, 2012
The Rural Andhra Pradesh Cardiovascular Prevention Study March 27, 2012:1188–96appropriately to treatment would be very unlikely to
experience a serious adverse effect because the rates of
severe side effects with these treatment modalities are
very low. In a situation in which there is a large and
growing burden of CVD that is untreated, there seems
little doubt that a management system along the lines of
ent Between Nonphysician and Physician Healthcare Workers U3 Agreement Between Nonphysician and Physician Healthcar
No
Recom
s reporting previous stroke (n  209)
tensin-converting enzyme inhibitor
tic
ose aspirin
s reporting previous myocardial infarction or angina (n  290)
tensin-converting enzyme inhibitor
blocker
ose aspirin
ased on the 490 high-risk individuals first seen by a nonphysician healthcare worker and sub
reement is the proportion of patients for whom exactly the same recommendations were ma
of Health Promotion Compared With Control on Primary and Secs Age 30 Years or Older4 Effects of Health Promotion Compared With Control on Primin Adults Age 30 Years or Older
Health Prom
(n  1,8
outcome
no. of correct answers to 6 knowledge questions 5.8
ary outcomes
no. of 6 lifestyle practices received advice about 5.5
no. of days eat fruit 2.0
no. of days eat green leafy vegetables 1.8
no. of days eat oily food 1.20
no. of days eat salty food 1.89
no. of days do light physical activity 6.7
no of days do medium/heavy physical activity 6.03
ion of high-risk individuals identified, % 42.3
o. of recommended drugs used by high-risk individuals 0.59
ion of high-risk on 2 recommended drugs, %* 15.8
ion not currently using tobacco, % 76.2
ody mass index, kg/m2 22.7
aist circumference, cm 83.0
ystolic BP, mm Hg 134.0
iastolic BP, mm Hg 81.0
ion with BP measured in past 24 months, % 58.9
ion with cholesterol measured in past 24 months, % 8.0
ion with blood or urine glucose assay in past 24 months, % 36.0
weighted mean values for high-risk individuals (or proportions of high-risk individuals) with the
pirin, beta-blocker, diuretic, angiotensin-converting enzyme inhibitor, or statin depending on disease
od pressure.that proposed here would produce substantial net popu-
lation health benefits (19). Approximately one third of
all vascular events occur in individuals with existing dis-
ease, meaning that treatment targeted at a very small
proportion of the population could deliver large absolute
health gains at low cost (24).
the Algorithmrkers Using the Algorithm
ician
tions, %
Physician
Recommendations, %
Overall
Agreement*
94.6 90.0
97.5 93.3
97.1 92.8
95.1 89.5
94.7 92.1
92.3 89.7
96.5 93.8
97.5 94.8
ly reviewed by a local village primary healthcare physician.
ry Outcomesand Se ndary Outcomes
Control
(n  1,844)
Mean Difference
(SE) p Value
5.9 0.08 (0.06) 0.15
5.5 0.03 (0.13) 0.82
2.0 0.02 (0.08) 0.77
1.8 0.02 (0.08) 0.78
1.38 0.19 (0.07) 0.01
1.75 0.14 (0.11) 0.25
6.8 0.01 (0.05) 0.78
5.99 0.04 (0.09) 0.63
44.2 1.92 (5.73) 0.74
0.63 0.04 (0.06) 0.57
17.9 2.1 (2.5) 0.41
74.3 1.87 (1.87) 0.31
22.9 0.2 (0.2) 0.39
84.0 0.5 (0.5) 0.32
135.0 0.50 (1.1) 0.65
81.0 0.4 (0.6) 0.53
59.2 0.29 (2.39) 0.90
6.3 1.7 (1.61) 0.31
32.6 3.46 (2.10) 0.11
differences presented as levels in the intervention group minus levels in the controlAgreem singTable e Wo
nphys
menda
Patient
Angio 98.5
Diure 99.5
Low-d 99.5
Statin 97.5
Patient
Angio 99.0
Beta- 97.9
Statin 99.0
Low-d 99.3Effects ondain AdultTable ary
otion
67)
Primary
Mean
Second
Mean
Mean
Mean
Mean
Mean
Mean
Mean
Proport
Mean n
Proport
Proport
Mean b
Mean w
Mean s
Mean d
Proport
Proport
Proport
Values are mean
state.
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strategy on the primary knowledge outcome, with a signifi-
cant benefit of health promotion observed only for the sec-
ondary outcome of mean number of days that oily foods
were eaten. Whether that one positive finding was a real
effect or simply reflects chance is not clear. We also ob-
served that for every component of the primary knowledge
outcome, the ability of respondents to answer correctly was
very high and much higher than we recorded in a similar
survey conducted in the same area a few years earlier (10).
It is possible that the knowledge levels increased in both
intervention and control villages due to a study effect or
that health promotion programs for diabetes and hyperten-
sion that were implemented in the area in the meantime
had significant positive effects on the knowledge of the
population. Regardless of the precise reason for the popula-
tion-wide increase in knowledge, the failure of the study to
detect an effect of the health promotion intervention could
have been limited by a ceiling effect. That said, the absence
of clear effects of the health promotion intervention on the
diverse range of secondary outcome measures does raise
uncertainty about the effectiveness of the health promotion
component.
Study limitations. This project gained substantially from
its large size, its randomized design, and its being con-
ducted in a real-world setting in rural India. It does, how-
ever, need to be interpreted in light of a number of poten-
tial weaknesses. First, there was no objective systematic
evaluation of all the high-risk patients included in the
study, and it is likely that there was some misclassification.
However, for many, there were supporting documents cited
by research staff, and in a previous validation exercise done
in this population, we showed that self-reported informa-
tion on CVD was fairly reliable (10,25). Given that mis-
classification is unlikely to be systematically different be-
tween the randomized groups, it is unlikely that this issue
could have substantially biased the main results. Second, it
was impossible to be sure that we were able to prevent
“contamination” of the geographically colocated control
sites with the respective intervention, and this is one further
possible explanation for the very high level of knowledge
seen in both intervention and control villages. Third, we
are unable to perform analyses that examined change in
outcomes (e.g., knowledge or drug use) over time because
we did not collect baseline information. This decision was
partly driven by cost and partly by our concern that a sur-vey of high-risk individuals at baseline could constitute an
intervention in its own right. Fourth, it is possible that with
a longer follow-up, the health workers in the intervention
villages may become more familiar with the process, and
the separation between randomized groups may have in-
creased. However, with longer follow-up, contamination
may have occurred at the control sites. We think that it is
unlikely that the effects on key outcomes would have
evolved because there is little likelihood that the main bar-
riers to treatment initiation would have been removed. Fi-
nally, as a result of the nature of the interventions under
investigation, the trial was necessarily conducted using an
open design with the consequent limitations. Efforts were,
however, made to perform outcome evaluations in a com-
pletely standardized way across all 44 participating villages.
Conclusions
These findings provide new insight into the potential for
NPHWs to deliver care for noncommunicable diseases in
rural India. Although additional work is required before a
policy change to support widespread implementation could
be considered, these data provide a strong rationale for the
further investigation of the role of NPHWs in the manage-
ment of the large chronic disease burden in India.
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